Up 14% in a month, is the Resmed share price just getting started?

The sleep apnoea and respiratory company's shares have had a fine start to FY23.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Resmed shares have pushed higher in the new financial year
  • Healthcare has proven to be a defensive sector in these volatile times
  • In the past 12 months, the Resmed share price is down almost 6%

The ResMed Inc (ASX: RMD) share price has been a solid gainer this past month of trade, up almost 14% in that time.

The company's shares have travelled from a low of $27.63 apiece on 25 May to their current price of $32.34 a share.

Meanwhile, healthcare shares are rebounding in June-July, with the S&P/ASX 200 Health Care Index (ASX: XHJ) up 13% in a month as well. The year-to-date performances of both Resmed and the index are charted below:

TradingView Chart

Has the Resmed share price got more?

The broker Morgans is bullish on the Resmed share price and has a price target of $37.95.

In a recent note, the broker said its long-term view on the healthcare player is positive, despite market volatility.

It made note of Resmed's digital platform that addresses kinks along the "healthcare value chain" in its assessment.

Meanwhile, 64% of brokers rate Resmed as a buy right now, according to Refinitiv Eikon data. The remainder say it's a hold, with no sell ratings on the share.

The consensus price target from this list is $33.93, a fraction above its current share price.

Sector-wise, healthcare shares could catch further bids in FY23 if recent trends prevail.

Researchers at Deloitte recently noted a number of catalysts are pushing the "clinical, financial, and operational transformation" of health care – COVID-19 potentially being one of these.

Moreover, the sector is projected to deliver an average earnings per share (EPS) growth of 30% in the second half of CY2022, according to Bloomberg data.

In the past 12 months, the Resmed share price is down 5.7%, falling just over 9% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could more than double Canaccord Genuity says

This company has more than one iron in the fire.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

This ASX biotech's shares just hit a new 12-month high, up more than 700% over a year. Here's why

Good news has this company's shares on the up.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Share Market News

Up 68% from a multi-year low. Are Telix shares a buy, sell or hold?

Telix shares crashed to just $8.63 per share in mid-February.

Read more »

Health professional working on his laptop.
Broker Notes

Are Orthocell shares a buy after crashing 7% yesterday?

These healthcare shares could be on discount right now.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

2 ASX healthcare shares I think can beat the market

Healthcare trends like ageing populations and rising demand can create long-term opportunities.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up 2,000% in a year, why this ASX healthcare stock is in focus today

4DMedical shares rise as multiple updates land across key markets.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »